PDCD1 and diabetes mellitus: Additionally, we examine the impact of JAK inhibitors on the programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) pathway and explore their prospective applications in managing immune checkpoint inhibitor-associated diabetes.